GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Financial Strength
中文

Aravive (STU:VE11) Financial Strength

: 0 (As of Sep. 2023)
View and export this data going back to 2017. Start your Free Trial

Aravive has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Aravive's interest coverage with the available data. Aravive's debt to revenue ratio for the quarter that ended in Sep. 2023 was 0.22. As of today, Aravive's Altman Z-Score is -76.66.


Competitive Comparison

For the Biotechnology subindustry, Aravive's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Aravive's Financial Strength distribution charts can be found below:

* The bar in red indicates where Aravive's Financial Strength falls into.



Aravive Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Aravive's Interest Expense for the months ended in Sep. 2023 was €0.00 Mil. Its Operating Income for the months ended in Sep. 2023 was €-8.35 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.29 Mil.

Aravive's Interest Coverage for the quarter that ended in Sep. 2023 is

GuruFocus does not calculate Aravive's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Aravive Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Aravive's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.987 + 0.287) / 10.328
=0.22

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Aravive has a Z-score of -76.66, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -76.66 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aravive  (STU:VE11) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Aravive has the Financial Strength Rank of 0.


Aravive Financial Strength Related Terms

Thank you for viewing the detailed overview of Aravive's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (STU:VE11) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines